The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Combination treatment of HCC with SBRT and immune checkpoint inhibition
Crit Rev Oncol Hematol. 2023 Oct 20:192:104191.doi:10.1016/j.critrevonc.2023.104191. Online ahead of print.
1Leeds Cancer Centre, St James University Hospital, Beckett Street, Leeds, UK.
2Leeds Cancer Centre, St James University Hospital, Beckett Street, Leeds, UK. Electronic address: mahazkayani@nhs.net.
Abstract
The treatment of unresectable or metastatic HCC has been significantly advanced in recent years by developments in both radiotherapy and systemic cancer therapies. Independently, both Stereotactic Ablative Body Radiotherapy (SBRT) and Immune Checkpoint Inhibitors (ICIs) are licensed for the treatment of these tumours. Building on the successes seen in other solid tumours, there is significant interest in exploring combination treatments. In this review article we briefly present the evidence base for the use of these treatments in patients with HCC. With reference to our current understanding of the immuno-oncology and radiobiology of HCCs, we demonstrate why combining these two modalities is of interest. Finally, we discuss the clinical trials that are currently underway or planned and the direction that future research may take.